LCTG 001
Alternative Names: LCTG-001Latest Information Update: 04 Nov 2020
At a glance
- Originator Lactiga
- Class Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Common variable immunodeficiency; COVID 2019 infections; Selective immunoglobulin A deficiency
Most Recent Events
- 15 Oct 2020 Lactiga enters into a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research for COVID-2019 infections
- 15 Oct 2020 Preclinical trials in Common Variable Immunodeficiency (Prevention) in USA (unspecified route)
- 15 Oct 2020 Preclinical trials in COVID-2019 infections in USA (unspecified route)